KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases

June 3-7, 2022; Chicago, Illinois
In this small cohort of patients with KRAS G12C–mutant NSCLC and active, untreated CNS metastases, adagrasib shows encouraging clinical activity and safety, yielding objective intracranial responses in a third of patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 141 KB
Released: June 13, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Related Content

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset on the molecular determinants for the selection of optimal therapy for patients with NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: July 29, 2022

Video featuring nursing perspective on biomarker testing in NSCLC and targeted therapy for actionable genomic alterations, from Clinical Care Options (CCO)

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Registered Nurses: 1.0 Nursing contact hour Released: July 27, 2022 Expired: July 26, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings